Literature DB >> 11169778

Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys.

D Frechilla1, A Cobreros, L Saldise, R Moratalla, R Insausti, M Luquin, J Del Río.   

Abstract

Cynomolgus monkeys (Macaca fascicularis) were chronically treated with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) until stable parkinsonism was reached. Two months later, monkeys were sacrificed and monoamine content was measured in different brain regions of the lesioned monkeys and of age-matched controls. 5-HT(1A) serotonin receptor density was measured in coronal sections labeled with [(3)H]8-OH-DPAT. As expected, dopamine was virtually nonexistent in the caudate nucleus and putamen of MPTP-treated monkeys. Serotonin levels were significantly reduced in different brain regions, particularly in the raphe nuclei. 5-HT(1A) receptor density of control animals was high in the hippocampus, notably in the CA1 field and also in the raphe nuclei, and much lower in the striatum, where 5-HT(1A) receptors showed a patchy distribution which corresponded to striosomes with poor calbindin immunostaining. 5-HT(1A) receptor density was reduced in hippocampal fields and in the raphe nuclei of parkinsonian monkeys. Conversely, in the severely lesioned striatal nuclei 5-HT(1A) receptor density was increased at caudal levels of the striatum, particularly in the putamen. The results tend to support the possibility of an increased synthesis of 5-HT(1A) receptors in brain regions with higher neuronal cell death. Upregulation of this 5-HT receptor subtype in the limbic compartment of the striatum may represent a compensatory event for the serotonergic dysfunction and associated mental disorders in neurodegenerative diseases such as Parkinson disease. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169778     DOI: 10.1002/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  23 in total

1.  Differential synaptology of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats.

Authors:  Dinesh V Raju; Deep J Shah; Terrence M Wright; Randy A Hall; Yoland Smith
Journal:  J Comp Neurol       Date:  2006-11-10       Impact factor: 3.215

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  Decreased response of interneurons in the medial prefrontal cortex to 5-HT₁A receptor activation in the rat 6-hydroxydopamine Parkinson model.

Authors:  Qiaojun Zhang; Shuang Wang; Lina Zhang; Huan Zhang; Hongfei Qiao; Xiaolin Niu; Jian Liu
Journal:  Neurol Sci       Date:  2014-02-22       Impact factor: 3.307

4.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

Review 5.  Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.

Authors:  B Scholtissen; F R J Verhey; H W M Steinbusch; A F G Leentjens
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

Review 6.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

7.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

8.  Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.

Authors:  Kristin B Dupre; Karen L Eskow; Christopher J Barnum; Christopher Bishop
Journal:  Neuropharmacology       Date:  2008-09-10       Impact factor: 5.250

9.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

10.  The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson's disease.

Authors:  Jian Cao; Jian Liu; Qiao-Jun Zhang; Tao Wang; Shuang Wang; Ling-Na Han; Qiang Li
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.